Yellow Fever A95
Conditions
Interventions
Group 1: Subjects after receiving yellow fever vaccination
Persons who receive either the first or the second yellow fever vaccination (according to the Stiko recommendation) will be included and bloo
Sponsors
Abteilung für Infektions- und Tropenmedizin, LMU Klinikum
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: - Eligible for Yellow fever vaccine due to travel or other reasons - Available for majority of time points
Exclusion criteria
Exclusion criteria: - Allergies or known sensitivity to yellow fever vaccine or components of the vaccine - Vaccination against Japanese encephalitis, FSME or Dengue 4 weeks prior or after the yellow fever vaccination - known positivity for acute/active blood borne diseases such as HIV, HepC or HepB -known condition leading to immuno-suppression e.g. solid cancer, known haematological abnormities - immuno-suppressive drugs such as systemic steroids, chemotherapy, immunosuppressive treatment of rheumatoid arthritis - other known exclusion criteria for yellow fever vaccine
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main feature is the reactivity against yellow fever antigens over time in different formats such as lateral flow, cell neutralization, ELISA, or ELECSYS asays. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes, related to the main outcomes, are reactivity against other infectious diseases with particular emphasis on other flaviviral diseases such as TBE, dengue, etc., as severe cross reactivities are described in the literature that are relevant to the specificity of the test. | — |
Countries
Germany
Contacts
Public ContactAndreas Wieser
Abteilung für Infektions- und Tropenmedizin, LMU Klinikum München
Outcome results
None listed